The complex crosstalk between the PI3K-AKT-mTOR pathway and multiple interacting cell signalling cascades can further promote prostate cancer progression and influence the sensitivity of prostate cancer cells to PI3K-AKT-mTOR-targeted therapies [221]. This evidence concerns the gene MTOR and prostate carcinoma.